1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Guangdong Zhongsheng Pharmaceutical Co., Ltd.

002317.SZ
Guangdong Zhongsheng Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
26.83
CNY
-2.16
- -
22.80BMarket Cap
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
002317.SZ
(Shenzhen Stock Exchange)

Recent

price

26.83

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.89
1.05
1.22
1.51
1.81
2.18
2.25
2.43
2.93
3.11
2.36
3.06
3.32
3.17
2.97
3.02
2.91
Revenue per Share
0.18
0.21
0.25
0.26
0.31
0.41
0.55
0.52
0.54
0.39
-0.53
0.35
0.4
0.32
-0.36
0.33
-0.24
Basic EPS, GAAP
0.01
-0.16
0.09
- -
-0.14
0.16
0.26
0.3
0.23
0.15
-0.02
0.52
-0.25
-0.21
0.13
-0.01
-0.29
Free Cash Flow per Basic Share
0.06
0.08
0.1
0.12
0.13
0.31
0.14
0.2
0.22
0.25
0.24
0.24
0.23
0.21
0.21
0.2
- -
Dividend per Share
0.5
0.7
0.82
1.18
1.35
2.06
2.46
2.59
2.92
3.04
2.35
2.51
2.63
2.72
2.13
2.2
2.16
Book Value per Share
1.88
1.99
2.12
2.26
2.35
1.1
2.77
2.6
2.48
2.73
3.52
3.39
3.48
4.05
3.85
3.85
3.88
Tangible Book Value per Share
721
717
726
722
724
724
753
808
807
815
805
793
805
823
831
836
826
Basic Weighted Avg Shares
641
751
886
1,090
1,309
1,578
1,692
1,964
2,362
2,532
1,896
2,429
2,676
2,611
2,467
2,523
2,403
Sales/Revenue/Turnover
19.66
20.18
19.77
16.63
17.07
20.26
25.31
23.46
21.9
19.05
14.82
16.48
14.75
13.48
11.13
12.71
12.23
Operating Margin (%)
15
20
26
30
50
63
68
70
78
98
99
96
100
121
125
125
- -
Depreciation Expense
132
151
182
188
225
297
414
420
436
318
-427
278
322
263
-299
276
-199
Net Income, GAAP
14.13
14.05
14.71
14.04
13
13.53
13.01
13.98
13.89
15.6
- -
11.25
14.38
11.9
- -
10.08
56.13
Effective Tax Rate (%)
20.53
20.05
20.48
17.22
17.16
18.81
24.48
21.39
18.45
12.55
-22.5
11.43
12.03
10.08
-12.12
10.93
-8.27
Profit Margin (%)
1,182
1,107
1,212
1,136
1,098
120
1,448
1,376
1,506
1,627
2,312
2,147
2,126
2,945
2,259
2,325
2,240
Working Capital
- -
- -
- -
6
- -
- -
- -
- -
348
235
232
313
290
98
- -
6
7
LT Debt
1,387
1,477
1,587
1,743
1,899
2,110
3,424
3,730
3,951
4,134
3,626
3,538
3,816
4,526
4,010
4,150
4,046
Total Equity
7.91
9.04
9.67
9.21
10.34
12.89
12.76
10.25
9.88
8.32
- -
8.49
7.68
6.19
- -
6.17
- -
Return on Invested Capital (%)
41.25
35.12
33.31
24.5
23.32
21.82
22.54
18.79
16.23
10.67
- -
13.09
13.74
10.15
- -
11.7
-3.86
Return on Capital (%)
43.8
35.04
33.24
25.92
24.48
24.01
24.77
21.28
19.58
13.14
-19.51
14.31
15.7
12.1
-14.94
15.29
-10.09
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
826
430
523
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
852
852
852
Market Capitalization
10,387
9,046
12,400

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
3,463
3,142
3,121
Cash, Cash Equivalents & STI
1,705
1,196
1,167
Accounts Receivable, Net
533
571
628
Inventories
441
378
363
Total Current Liabilities
1,203
801
881
Payables & Accruals
- -
- -
- -
ST Debt
826
430
523
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.56%
3.22%
3.48%
Free Cash Flow
-325.39%
-635.57%
-110.01%
Net Income, GAAP
-78.97%
-114.63%
-192.18%
Sales/Revenue/Turnover
5.83%
6.52%
2.24%
Total Cash Common Dividend
1.16%
-2.75%
-0.38%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
641
723
544
559
2,467
2025
634
665
634
- -
2,523
2026
624
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
- -
- -
- -
-0.36
2025
0.1
- -
- -
- -
0.33
2026
0.12
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.21
2025
- -
- -
- -
- -
0.2
2026
- -
- -
- -
- -
- -
Similar Companies
Koa Shoji Holdings Co.,Ltd. (9273.T)
Red White & Bloom Brands Inc. (RWB.CN)
The Greenrose Holding Company Inc. (GNRSU)
Panacea Life Sciences Holdings, Inc. (PLSH)
Radnostix, Inc. (INIS)
Journey Medical Corporation (DERM)
Business
Guangdong Zhongsheng Pharmaceutical Co., Ltd. researches, develops, produces and sells pharmaceutical products principally in China with a focus on ophthalmology, cardiovascular, cerebrovascular, respiratory, digestive, diabetes, tumor and senile degenerative diseases; the company offers Chinese patent medicines including compound thrombotron series products, brain embolization capsules, compound salvia tablets, zongsheng pills series products and heat-clearing and dehumidifying granules, as well as chemical medicines such as liritvir tablets, onradivir tablets, cefixime dispersible tablets, cefradine capsules, ribavirin tablets, rifampicin capsules, azelastine hydrochloride eye drops, cyclosporine eye drops and loratadine tablets. Founded in 1979 and headquartered in Dongguan, Guangdong Province at the Information Industry Park in Shilong Town's Xihu Industrial Zone, the company operates ten subsidiaries and four major production bases targeting hospitals, retail pharmacies and healthcare facilities primarily in China with over 85% of sales from the domestic market. In 2024, the company reported revenue of 2.47 billion yuan, a 5.5% year-on-year decline amid asset impairment provisions of 550 million yuan including goodwill impairments for subsidiaries Xianqiang Pharmaceutical and Yishu Pharmaceutical and R&D project write-downs for items such as ZSP1602 and ZSP1241; it recently extended guarantees up to 2 billion yuan for subsidiaries including Zhongsheng Medical Trade and Yikang Pharmaceutical to support operations and financing with banks like China Bank and CMB.